Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Chugai Pharmaceutical : Notice of Revisions to Dividend Forecast for Fiscal Year Ending December 31, 2021

10/25/2021 | 07:27am EST

Chugai Pharmaceutical Co., Ltd. announced that the Company resolved at the meeting of its Board of Directors held to revise the dividend forecast per share as described below.

1. Reasons for the revision

Reflecting the significant changes in the business environment, year-end dividend forecast has been revised to undecided. The year-end dividends will be decided after the fiscal year end based on basic profit distribution principles.

Regarding income distribution, taking into account the strategic funding needs and earning prospects, Chugai aims for a consolidated dividend payout ratio of 45% on average in comparison with Core EPS to provide a stable allocation of profit to all shareholders.

Contact:

Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group

Corporate Communications Dept.

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

Investors

Chugai Pharmaceutical Co., Ltd.

Investor Relations Group

Corporate Communications Dept.

Takayuki Sakurai

Tel: +81-3-3273-0554

E-mail: ir@chugai-pharm.co.jp

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD. 0.85% 3665 End-of-day quote.-33.40%
ROCHE HOLDING AG -0.11% 363 Delayed Quote.17.49%
All news about CHUGAI PHARMACEUTICAL CO., LTD.
01:12aCHUGAI PHARMACEUTICAL : Towa Pharmaceutical Receives Approval for Authorized Generic Versi..
PU
12/02Chugai Launches a New Educational Website 'So-Zo LABO' Aiming for a Society that Embrac..
AQ
12/01CHUGAI PHARMACEUTICAL : Launches a New Educational Website “So-Zo LABO” Aiming..
PU
11/26Chugai Pharmaceutical Co. - Anti Cancer Agent Herceptin Approved for Additional Indicat..
AQ
11/25CHUGAI PHARMACEUTICAL : Anti-Cancer Agent Herceptin Approved for Additional Indication of ..
PU
11/23Beijing IP Court To Hear China's First Case Of Patent Linkage
AQ
11/18CHUGAI PHARMACEUTICAL : Personnel Changes
PU
11/18CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
11/16CHUGAI PHARMACEUTICAL : Atea Announces Update on Collaboration with Roche for AT-527
PU
11/16Chugai Continuously Selected in the 'DJSI World,' a Global ESG Investment Index
AQ
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD.
More recommendations
Financials
Sales 2021 975 B 8 597 M 8 597 M
Net income 2021 292 B 2 577 M 2 577 M
Net cash 2021 461 B 4 065 M 4 065 M
P/E ratio 2021 20,7x
Yield 2021 1,85%
Capitalization 6 044 B 53 464 M 53 311 M
EV / Sales 2021 5,73x
EV / Sales 2022 5,42x
Nbr of Employees 7 555
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 3 676,00 JPY
Average target price 4 785,38 JPY
Spread / Average Target 30,2%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-33.40%53 304
JOHNSON & JOHNSON-0.18%413 555
ROCHE HOLDING AG17.62%341 509
PFIZER, INC.44.09%297 706
NOVO NORDISK A/S64.51%243 534
ELI LILLY AND COMPANY47.55%224 726